BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study More: BiomX phage therapy shows potent effect in cystic fibrosis trial Source: News
read more
Funding to support lead candidate targeting FAP and pipeline expansion More: Actithera closes .5m Series A to advance radioligand therapy platform Source: News
read moreAs biosimilars struggle to live up to their promise of cutting costs and improving access to biologic medicines for U.S. patients, more than 39 advocacy groups are championing recent bipartisan efforts to cut through the bureaucracy that they believe has
read moreBiopharma layoff rounds reported this May hit an all-time high, with 29 RIFs occurring—the most of any month reported over the last four years Fierce Biotech has spent tracking the measure. More: Biopharma layoffs for first half of the year
read more
New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients More: VarmX secures US approval to begin phase 3 trial of urgent surgery treatment Source: News
read more
Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas More: Clinical Researcher of the Year – The Americas Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals